Altavant’s lead candidate is rodatristat ethyl*, the prodrug of rodatristat, a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production. By lowering levels of serotonin in the circulation and in pulmonary tissues, rodatristat may represent a disease-modifying treatment for diseases characterized by pathological serotonin signaling. These diseases include pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) and sarcoidosis.
*For ease of reading, this website sometimes uses the name “rodatristat” to refer to the prodrug rodatristat ethyl in addition to the active moiety.
|Rodatristat ethyl||Pulmonary Arterial Hypertension (PAH)||Phase 2|
|Idiopathic Pulmonary Fibrosis (IPF)||Research|
|ALTA-2530||Bronchiolitis Obliterans Syndrome||IND Enabling|
|Next-Generation TPH Inhibitors||Oral agents for multiple indications||Research|
|Alternative routes of administration for multiple indications||Research|
|Compound||Disease||Research||IND Enabling||Phase 1||Phase 2||Phase 3|
|Rodatristat Ethyl||Pulmonary Arterial Hypertension (PAH)|
PAH STUDY NOW ENROLLING
|Idiopathic Pulmonary Fibrosis (IPF)|
|ALTA-2530||Transplant-associated bronchiolitis obliterans syndrome|
|Chemical-induced bronchiolitis obliterans syndrome|
* Partnered with BARDA / NIAID
|Next-Generation TPH Inhibitors||Oral agents for multiple indications|
|Alternative routes of administration of multiple indications|